Detalhe da pesquisa
1.
Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.
Am Heart J
; 215: 178-186, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31349109
2.
Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia.
Digit Biomark
; 7(1): 54-62, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404864
3.
Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia.
Parkinsonism Relat Disord
; 109: 105355, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905719
4.
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia.
J Parkinsons Dis
; 12(6): 1991-2004, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35694933
5.
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Hepatol Commun
; 2(5): 561-570, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29761171
6.
Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.
Diabetes Care
; 34(7): 1511-3, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21593301